Skip to main content
Fig. 2 | BMC Endocrine Disorders

Fig. 2

From: Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study

Fig. 2

Estimated probabilities of achieving categorical outcomes with IDeglira and ICT during follow-up. a – HbA1c ≤7.0% (53.0 mmol/mol). b – HbA1c ≤7.0% (53.0 mmol/mol) without hypoglycaemia. c – HbA1c ≤7.0% (53.0 mmol/mol) without weight gain. d – HbA1c ≤7.0% (53.0 mmol/mol) without hypoglycaemia or weight gain. Estimated for a person with the following baseline characteristics: 62 years of age, HbA1c of 8.4% (68.3 mmol/mol), diabetes duration of 9.1 years, body weight of 91 kg, body mass index of 32.0 kg/m2 using generalized least squares regression (n = 299 people, n = 889 observations). The coloured lines represent the treatment estimates, while the shaded areas show 95% confidence intervals around the estimated values. ICT, intensified conventional insulin treatment; IDegLira, insulin degludec/liraglutide

Back to article page